phase 2
ii 2
multicenter 2
trial 1
hypercvad 1
mtxarac 1
rituximab 1
patients 2
previously 1
untreated 1
mantle 2
cell 2
lymphoma 2
swog 1
study 1
bortezomib 1
relapsed 1
refractory 1
